Top Companies in the Cell & Gene Therapy Logistics Market
- Cryoport, Inc.
- Marken (a UPS Company)
- World Courier / AmerisourceBergen
- Thermo Fisher Scientific / Patheon
- Catalent, Inc.
- BioLife Solutions
- Brooks Life Sciences
- DHL / Cryopdp
- Lonza / CDMO partners
- Almac Group / Arvato Supply Chain Solutions
- Biocair
- Vineti
- TrakCel
- SAVSU Technologies / Hypertrust Patient Data Care
- Stafa Cellular Therapy / Stafa Logistics
- Be The Match BioTherapies
- Modality Solutions
- Biostor / Yourway Biopharma Services
- Haemonetics / McKesson specialty logistics arms
- Cryogenic shipper manufacturers & suppliers
Market Growth
The global cell & gene therapy logistics market size is estimated at US$ 1.45 billion in 2024, is projected to grow to US$ 1.62 billion in 2025, and is expected to reach around US$ 4.33 billion by 2034. The market is projected to expand at a CAGR of 11.54% between 2025 and 2034.
Cell & Gene Therapy Logistics Market Trends
Increasing government funding in the cell and gene therapy logistics to support the high costs and long development timelines associated with these therapies, which contributes to the growth of the market.
For instance,
- In March 2025, Bharat Biotech invested $75 million in its first cell and gene therapy facility in Telangana, India, and launched novel therapies in three years. The company is targeting oncology and rare diseases, and is working on cost-effective treatments for the Indian market. They are also considering exporting these advanced therapies.
Increasing partnership among the government organizations and biotech companies contributes the growth of the growth of the market.
For Instance,
- In June 2024, Cryoport, Inc., a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd., a global contract development and manufacturing organization for cell and gene therapies, announced a strategic partnership to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products to support the advancement of cell and gene therapies.
Cell & Gene Therapy Logistics Market – Value Chain Analysis
R&D
Research and development of gene and cell therapy logistics includes preclinical testing in laboratories and animal models, followed by an investigational new drug (IND) application. If accepted, clinical trials are conducted in three phases to assess efficacy, safety, and dosage.
Key Players: Amgen, Biogen, Bristol-Myers Squibb, Novartis, and Gilead Sciences
Clinical Trials
Clinical trials for cell and therapy logistics include the process of supply and logistics includes sourcing, packaging, storing, labelling, and distributing investigational medicinal products (IMPs), and associated materials vital for a clinical trial.
Key Players: Biocair, Modality Solutions, BioLife Solutions, Marken, and Yourway
Patient Support and Services
Cell and gene therapy logistics management requires these strategies, including understanding the protocol, the patient’s ailment stage, present comorbidities, the effectiveness of apheresis, tracking of cells, coordination of handling, shipping, and management to the patient, and reconciliation of the unused product.
Key Players: Krystal Biotech and CRISPR Therapeutics
Latest Announcements by Industry Leaders
In March 2025, Frederik Brabant, MD, Chief Medical Strategy Officer at Corti, stated, “Radiologists require extreme precision in highly technical language while dictating notes. Our specialized dictation technology meets these unique needs, enabling faster, more accurate reporting while reducing cognitive load - and the real-time component is crucial, as radiologists need to follow the cursor while dictating to maintain their train of thought.”
Recent Developments in the Cell & Gene Therapy Logistics Market
- In June 2024, Cryoport, Inc., a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd., a global contract development and manufacturing organization for cell and gene therapies, announced a strategic partnership to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products to support the advancement of cell and gene therapies.
- In July 2025, DHL Group announced a strategic investment of €2 billion over the next five years to enhance its logistics capabilities in the life sciences and healthcare sector. This investment supports the Group's "Strategy 2030" and reinforces DHL's commitment to helping healthcare customers grow, innovate, and serve patients more effectively worldwide.
- In September 2024, Cryoport, Inc., a global leader in supply chain solutions for the life sciences industry, and SK Pharmteco, a global contract development and manufacturing organization, announced a strategic collaboration to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
